{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:17:15Z","timestamp":1792451835269,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>Metastatic renal cell carcinoma (mRCC) treatment with immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor\u2013tyrosine kinase inhibitors (VEGF-TKIs) yields durable benefit in a subset of patients, yet primary resistance remains frequent. Emerging data implicate the gut microbiome as a determining factor of systemic therapy efficacy. This review systematically evaluates clinical evidence on antibiotics (ATBs), probiotics, dietary interventions, and fecal microbiota transplantation (FMT) in modulating the gut microbiome to influence outcomes in adult patients with mRCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible studies included adult (\u2265\u200918\u00a0year) RCC cohorts receiving microbiome interventions versus standard care, reporting objective response rate (ORR), progression-free survival (PFS), overall survival (OS), or immune-related adverse events (irAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings and limitations<\/jats:title>\n                    <jats:p>\n                      Six studies (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20094738) met criteria: three retrospective cohorts linking peri-ICI ATB exposure to inferior ORR (12.9\u201334.8%), shorter PFS (hazard ratios [HR] 1.96\u20133.10), and OS (HR 3.5); one prospective RCT (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920) demonstrating engraftment of\n                      <jats:italic>Bifidobacterium animalis<\/jats:italic>\n                      yogurt during VEGF-TKI therapy with enrichment of\n                      <jats:italic>Akkermansia muciniphila<\/jats:italic>\n                      and trends to longer PFS; and one phase II RCT abstract (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200950) showing FMT from an ICI responder improved 1-year PFS (66.7% vs. 35.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.036) and ORR (54% vs. 28%) in pembrolizumab\u2009+\u2009axitinib recipients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and clinical implications<\/jats:title>\n                    <jats:p>ATB-induced dysbiosis compromises ICI efficacy in mRCC; probiotics and FMT exhibit promise to augment immunotherapy and targeted therapy. Prospective, biomarker-driven RCTs with standardized microbiome assays are needed before routine clinical implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-026-06386-1","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T14:26:53Z","timestamp":1776004013000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gut microbiome impact on systemic therapy outcomes in metastatic renal cell carcinoma: a systematic review"],"prefix":"10.1007","volume":"44","author":[{"given":"Filippo","family":"Gavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bracco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Testori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Fettucciari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Panio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Assumma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazario","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Ragonese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Turri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Bientinesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ciccarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Iacovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T.","family":"Kr\u00f6ner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Sighinolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,12]]},"reference":[{"key":"6386_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"6386_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041071","author":"F Lasorsa","year":"2023","unstructured":"Lasorsa F, di Meo NA, Rutigliano M, Milella M, Ferro M, Pandolfo SD et al (2023) Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11041071","journal-title":"Biomedicines"},{"key":"6386_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D et al (2019) Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"key":"6386_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha S-Y, Porta C, Eto M, Powles T et al (2021) Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2035716","journal-title":"N Engl J Med"},{"key":"6386_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510016","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F et al (2015) Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1510016","journal-title":"N Engl J Med"},{"key":"6386_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","volume":"20","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K et al (2022) Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20:71\u201390. https:\/\/doi.org\/10.6004\/jnccn.2022.0001","journal-title":"J Natl Compr Canc Netw"},{"key":"6386_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1214575","author":"KE Beckermann","year":"2017","unstructured":"Beckermann KE, Johnson DB, Sosman JA (2017) PD-1\/PD-L1 blockade in renal cell cancer. Expert Rev Clin Immunol. https:\/\/doi.org\/10.1080\/1744666X.2016.1214575","journal-title":"Expert Rev Clin Immunol"},{"key":"6386_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx151","author":"MB Atkins","year":"2017","unstructured":"Atkins MB, Clark JI, Quinn DI (2017) Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdx151","journal-title":"Ann Oncol"},{"key":"6386_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3290","author":"V Matson","year":"2018","unstructured":"Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L et al (2018) The commensal microbiome is associated with anti\u2013PD-1 efficacy in metastatic melanoma patients. Science. https:\/\/doi.org\/10.1126\/science.aao3290","journal-title":"Science"},{"key":"6386_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV et al (2018) Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients. Science 359:97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236","journal-title":"Science"},{"key":"6386_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R et al (2018) Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors. Science 359:91\u20137. https:\/\/doi.org\/10.1126\/science.aan3706","journal-title":"Science"},{"key":"6386_CR12","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41551-021-00749-2","volume":"5","author":"K Han","year":"2021","unstructured":"Han K, Nam J, Xu J, Sun X, Huang X, Animasahun O et al (2021) Generation of systemic antitumour immunity via the in situ modulation of the gut microbiome by an orally administered inulin gel. Nat Biomed Eng 5:1377\u201388. https:\/\/doi.org\/10.1038\/s41551-021-00749-2","journal-title":"Nat Biomed Eng"},{"key":"6386_CR13","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM et al (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti\u2013PD-L1 efficacy. Science 350:1084\u20139. https:\/\/doi.org\/10.1126\/science.aac4255","journal-title":"Science"},{"key":"6386_CR14","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M V\u00e9tizou","year":"2015","unstructured":"V\u00e9tizou M, Pitt JM, Daill\u00e8re R, Lepage P, Waldschmitt N, Flament C et al (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350:1079\u201384. https:\/\/doi.org\/10.1126\/science.aad1329","journal-title":"Science"},{"key":"6386_CR15","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00262-020-02786-3","volume":"70","author":"F Meriggi","year":"2021","unstructured":"Meriggi F, Zaniboni A (2021) Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature. Cancer Immunol Immunother 70:1511\u20137. https:\/\/doi.org\/10.1007\/s00262-020-02786-3","journal-title":"Cancer Immunol Immunother"},{"key":"6386_CR16","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","volume":"29","author":"L Derosa","year":"2018","unstructured":"Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H et al (2018) Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol 29:1437\u201344. https:\/\/doi.org\/10.1093\/annonc\/mdy103","journal-title":"Ann Oncol"},{"key":"6386_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.euo.2019.09.001","volume":"3","author":"A-KA Lalani","year":"2020","unstructured":"Lalani A-KA, Xie W, Braun DA, Kaymakcalan M, Boss\u00e9 D, Steinharter JA et al (2020) Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. Eur Urol Oncol. 3:372\u201381. https:\/\/doi.org\/10.1016\/j.euo.2019.09.001","journal-title":"Eur Urol Oncol."},{"key":"6386_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.eururo.2020.04.044","volume":"78","author":"L Derosa","year":"2020","unstructured":"Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E et al (2020) Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. Eur Urol 78:195\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2020.04.044","journal-title":"Eur Urol"},{"key":"6386_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04189-2","author":"S Porcari","year":"2026","unstructured":"Porcari S, Ciccarese C, Heidrich V, Rondinella D, Quaranta G, Severino A et al (2026) Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-04189-2","journal-title":"Nat Med"},{"key":"6386_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/cam4.3569","volume":"10","author":"N Dizman","year":"2021","unstructured":"Dizman N, Hsu J, Bergerot PG, Gillece JD, Folkerts M, Reining L et al (2021) Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma. Cancer Med 10:79\u201386. https:\/\/doi.org\/10.1002\/cam4.3569","journal-title":"Cancer Med"},{"key":"6386_CR21","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1038\/s41591-024-03086-4","volume":"30","author":"H Ebrahimi","year":"2024","unstructured":"Ebrahimi H, Dizman N, Meza L, Malhotra J, Li X, Dorff T et al (2024) Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med 30:2576\u201385. https:\/\/doi.org\/10.1038\/s41591-024-03086-4","journal-title":"Nat Med"},{"key":"6386_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nrc.2017.13","volume":"17","author":"S Roy","year":"2017","unstructured":"Roy S, Trinchieri G (2017) Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer 17:271\u201385. https:\/\/doi.org\/10.1038\/nrc.2017.13","journal-title":"Nat Rev Cancer"},{"key":"6386_CR23","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/ijc.32003","volume":"145","author":"D Chen","year":"2019","unstructured":"Chen D, Wu J, Jin D, Wang B, Cao H (2019) Fecal microbiota transplantation in cancer management: Current status and perspectives. Int J Cancer 145:2021\u201331. https:\/\/doi.org\/10.1002\/ijc.32003","journal-title":"Int J Cancer"},{"key":"6386_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2268982","volume":"19","author":"S Bibb\u00f2","year":"2023","unstructured":"Bibb\u00f2 S, Porcari S, Del Vecchio LE, Severino A, Mullish BH, Ianiro G et al (2023) Gut microbiota and immunotherapy of renal cell carcinoma. Human Vaccines & Immunotherapeutics 19:2268982. https:\/\/doi.org\/10.1080\/21645515.2023.2268982","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"6386_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-025-01276-2","author":"F Gavi","year":"2025","unstructured":"Gavi F, Sighinolfi MC, Pallotta G, Assumma S, Panio E, Fettucciari D et al (2025) Multiomics in Renal Cell Carcinoma: Current Landscape and Future Directions for Precision Medicine. Curr Urol Rep. https:\/\/doi.org\/10.1007\/s11934-025-01276-2","journal-title":"Curr Urol Rep"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06386-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06386-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06386-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:51:56Z","timestamp":1781646716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06386-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,12]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6386"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06386-1","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,12]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval, Consent to Participate, and Consent to Publish declarations"}},{"value":"not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"302"}}